With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.406212-51-9,1-tert-Butyl 3-methyl 4-hydroxypiperidine-1,3-dicarboxylate,as a common compound, the synthetic route is as follows.
(A) 1 -ferf-buty. 3-methyl 4-(ferf-butyidi methy.si.yioxy)piperidi ne-1 ,3- dicarboxylaie.A mixture of methyl 4-hydroxypiperidine-3-carboxylate (3.18 g, 20 mmol), aqueous sodium hydrogen carbonate (30 mL, 1 M), di-fe/t-butyl dicarbonate (4.37 g, 20 mmol) and dichloromethane (30 mL) was stirred for 15 hours. The phases were separated and dichloromethane phase was dried over anhydrous sodium sulfate and filtrated. The filtrate was diluted to 200 mL. To the resulted solution was added imidazole (1 .64 g, 24 mmol), DMAP (0.488 g, 4 mmol), and TBDMSCI (3.62 g, 24 mmol) sequentially. The reaction mixture was stirred at room temperature for 40 hours. The mixture was washed with 1 N HCI solution, NaHCO3 solution and brine sequentially and dried over anhydrous sodium sulfate. Filtration and concentration gave the crude compound which was used directly in the next step. MS (m/z): 274 (M-Boc+H)+.
406212-51-9, As the paragraph descriping shows that 406212-51-9 is playing an increasingly important role.
Reference：
Patent; HUTCHISON MEDIPHARMA LIMITED; SU, Wei-Guo; DENG, Wei; JI, Jianguo; WO2012/167423; (2012); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem